Quazepam

Quazepam

Clinical data
Trade names	Doral
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a684001
Pregnancy category	AU: D US: X (Contraindicated)
Routes of administration	Oral
ATC code	N05CD10 (WHO)
Legal status
Legal status	CA: Schedule IV US: Schedule IV
Pharmacokinetic data
Bioavailability	29–35%
Metabolism	Hepatic
Biological half-life	39 hours
Excretion	Renal
Identifiers
IUPAC name 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione
CAS Number	36735-22-5 Y
PubChem CID	4999
IUPHAR/BPS	7288
DrugBank	DB01589 Y
ChemSpider	4825 Y
UNII	JF8V0828ZI
KEGG	D00457 Y
ChEMBL	CHEMBL1200472 N
ECHA InfoCard	100.048.329
Chemical and physical data
Formula	C17H11ClF4N2S
Molar mass	386.795 g/mol
3D model (Jmol)	Interactive image
SMILES FC(F)(F)CN1C(=S)C/N=C(\c2cc(Cl)ccc12)c3ccccc3F
InChI InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2 Y Key:IKMPWMZBZSAONZ-UHFFFAOYSA-N Y
NY (what is this?)

Quazepam (marketed under brand names Doral, Dormalin) is a benzodiazepine derivative drug developed by the Schering Corporation in the 1970s. Quazepam is indicated for the treatment of insomnia including sleep induction and sleep maintenance. Quazepam induces impairment of motor function and has hypnotic and anticonvulsant properties with less overdose potential than other benzodiazepines. Quazepam is an effective hypnotic which induces and maintains sleep without disruption of the sleep architecture. Quazepam is a trifluoroalkyl type of benzodiazepine, like fletazepam, halazepam, triflubazam and triflunordazepam. Quazepam is unique amongst benzodiazepines in that it selectively targets the GABA_A α₁ subunit receptors which are responsible for inducing sleep. Its mechanism of action is very similar to zolpidem and zaleplon in its pharmacology and can successfully substitute for zolpidem and zaleplon in animal studies.

Quazepam is used for short-term treatment of insomnia related to sleep induction or sleep maintenance problems and has demonstrated superiority over other benzodiazepines such as temazepam. It had a fewer incidence of side effects than temazepam, including less sedation, amnesia, and less motor-impairment. Usual dosage is 7.5 to 15 mg orally at bedtime.

Quazepam is effective as a premedication prior to surgery.

Quazepam has fewer side effects than other benzodiazepines and less potential to induce tolerance and rebound effects. There is significantly less potential for quazepam to induce respiratory depression or to adversely affect motor coordination than other benzodiazepines. The different side effect profile of quazepam may be due to its more selective binding profile to type 1 benzodiazepine receptors.